The ZGC Forum showcased advancements in China's brain-computer interface technology, with notable developments like Beinao-1 and Beinao-2.
The recent ZGC Forum in Beijing, held from March 25 to 29, highlighted significant innovations in brain-computer interface (BCI) technology, drawing considerable attention from experts and attendees alike.
According to Zhao Jizong, a neurosurgery expert at the Chinese Academy of Sciences, "The technology is advancing rapidly, and its applications are expanding."
Among the notable projects presented were Beinao-1 and Beinao-2. Beinao-1 is a semi-invasive system that has been successfully implanted in seven patients, leading to partial recovery of motor and speech functions. Beinao-2, an invasive implant featuring flexible electrodes that integrate into the brain, is currently undergoing extensive animal testing and is expected to begin clinical trials in 2026. NeuCyber Neurotech, the developer, acknowledged that its technology is approximately three years behind Elon Musk's Neuralink.
BCI technology facilitates a direct communication link between the brain and external devices, allowing users to control machines by interpreting brain signals. This innovation offers new possibilities for patients with neurological impairments.
China's government has prioritized BCI development, implementing policies to foster research and application in this sector. Experts from various institutions gathered at the forum to discuss advancements and industrial applications of BCI technology.
Gu Xiaosong, an academician at the Chinese Academy of Engineering, noted a significant acceleration in BCI developments in China since 2025, with many technologies moving toward practical application.
In cities like Beijing, Tianjin, and Guangzhou, specialized BCI clinics have emerged, utilizing domestic solutions for disease diagnosis and motor function rehabilitation. Jizong pointed out the pressing need for innovative solutions, as over 3.7 million patients in China suffer from neurological diseases.
Local authorities are actively fostering the BCI industry, with 27 companies already operating in Beijing's Haidian District. The aim is to attract around 100 small and medium enterprises by 2030, promoting the integration of BCI products across various sectors.
Yao Dezhong, director of the Sichuan Institute of Neuroscience, expressed optimism about the practical applications of BCI in China within the next three to five years. He highlighted the country's advantages, including a large population and high patient demand, as key factors driving this progress.
While American companies like Neuralink focus on invasive techniques, Chinese researchers are also exploring non-invasive options with wider clinical applicability, despite potential signal quality compromises. Notably, China has recently approved its first neuroimplant for commercial use, marking a significant milestone in the field.
